Nxera Pharma, the Japan-based company with an R&D facility on Granta Park, has launched insomnia treatment QUVIVIQ (daridorexant) with Shionogi & Co.
QUVIVIQ is an oral dual orexin receptor antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.
Chris Cargill, president and CEO of Nxera Pharma
Nxera is the approval holder and will be responsible in part for provision of drug product. Shionogi will be solely responsible for distribution and sales activities for QUVIVIQ in Japan under the commercial partnership agreement with Nxera Pharma announced on 1 October, 2024.
For Nxera, the milestone highlights its ability to develop novel therapeutics and reinforces its ambition to be a partner of choice for companies looking to develop and commercialise new therapeutics for Japan.
Together, Nxera and Shionogi “are committed to deliver QUVIVIQ as quickly as possible as a product that has the potential to meet the needs of insomnia patients for a long time to come”.